Discontinued — last reported Q4 '22
Edwards Lifesciences EPS (Basic, Discontinued) decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 100.0%, from $-0.01 to $0.00. Over 3 years (FY 2022 to FY 2025), EPS (Basic, Discontinued) shows a downward trend with a -54.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Provides transparency into how much of the reported EPS is driven by non-recurring divestment activities rather than core operations.
The portion of basic earnings per share that is derived specifically from discontinued operations. It helps investors is...
Specific to companies undergoing significant portfolio changes; not a standard recurring performance metric.
eps_basic_discontinued| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.08 | $0.08 | $0.08 | $0.08 | $0.07 | $0.09 | $0.08 | $0.06 | $0.04 | $0.00 | $4.53 | $0.07 | -$0.01 | -$0.01 | $0.00 | $0.05 | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -12.5% | +28.6% | -11.1% | -25.0% | -33.3% | -100.0% | — | -98.5% | -114.3% | +0.0% | +100.0% | — | -100.0% |
| YoY Change | — | — | — | — | -12.5% | +12.5% | +0.0% | -25.0% | -42.9% | -100.0% | >999% | +16.7% | -125.0% | — | -100.0% | -28.6% | +100.0% |